当前开发帕金森病血液检测方法所面临的挑战。
Current Challenges Towards the Development of a Blood Test for Parkinson's Disease.
机构信息
The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064-3037, USA.
出版信息
Diagnostics (Basel). 2014 Oct 22;4(4):153-64. doi: 10.3390/diagnostics4040153.
Parkinson' disease (PD) is the second most prevalent neurodegenerative disease worldwide. To date, there is no disease-modifying agent, and current medical treatment only provides symptomatic benefits. Early diagnosis of PD would be useful in clinical practice to identify patients for clinical trials, test potential drugs and neuroprotective agents and track their therapeutic effect. Considerable progress has been made in the discovery and validation of diagnostic biomarkers for PD. In particular, blood-based biomarkers have shown promise in identifying PD patients in samples from independent clinical trials. Evaluation of these biomarkers in de novo patients and individuals at risk for PD remains a top priority. Here, we review the current advances and challenges toward the clinical translation of these biomarkers into a blood-based test for PD.
帕金森病（PD）是全球第二大常见的神经退行性疾病。迄今为止，尚无疾病修饰剂，目前的医学治疗只能提供对症益处。PD 的早期诊断在临床实践中很有用，可以识别出适合临床试验的患者，测试潜在的药物和神经保护剂，并跟踪其治疗效果。在 PD 的诊断生物标志物的发现和验证方面已经取得了相当大的进展。特别是，基于血液的生物标志物在从独立临床试验的样本中识别 PD 患者方面显示出了前景。在新发患者和 PD 风险个体中评估这些生物标志物仍然是当务之急。在这里，我们综述了将这些生物标志物转化为基于血液的 PD 检测方法的临床转化的最新进展和挑战。
Zotero 插件